摘要
骨硬化蛋白作为骨-血管轴之间的重要信使,在血管钙化发生发展中起着关键性作用,但其机制较为复杂。目前研究证明,骨硬化蛋白是一种骨细胞特异性糖蛋白,被认为是一种有效的骨形成抑制剂;通过抑制Wnt/β-连环蛋白信号传导激活所需的特定的共同受体而发挥其生物学效应。血清骨硬化蛋白水平可能反映了骨代谢,并且可能用作终末期肾病(ESRD)患者中低转换性骨疾病和肾性骨营养不良的标志物。然而,骨硬化蛋白与血管钙化的相互作用和慢性肾脏病(CKD)患者的临床预后尚不清楚。尽管如此,抗硬化蛋白抗体可能是一种新的治疗方法。本文旨在了解骨硬化蛋白的基本结构及其生物学活性,同时对其与慢性肾脏病及血管钙化的关系做一综述,并提出抗硬化蛋白抗体治疗在CKD患者中的应用。
As an essential messenger between bones and vessel axis ,sclerostin plays a key role in development and progression of vascular calcification;however,its mechanism is complicated.Current studies have demonstrated,sclerostin is an osteocyte-specific glycoprotein,which is considered as an effective inhibitor of bone formation;its biological effects are exerted by inhibiting the specific co-receptors required for Wnt/β-catenin signaling activation.Thus,serum sclerostin levels may reflect bone metabolism,and may be used as a marker of low and middle turnover bone disease and renal osteodystrophy in patients with end stage renal disease (ESRD).In spite of this,anti-sclerostin antibodies may be a novel therapy.This article is supposed to understand basic structure and biological activity of sclerostin,meanwhile review its relationship with chronic kidney diseases and vascular calcification,and comp up with application of anti-sclerostin antibody therapy in patients with CKD.
作者
彭琼瑶
刘玲
PENG Qiong-yao;LIU Ling(Department of Nephrology,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)
出处
《临床肾脏病杂志》
2019年第3期218-222,共5页
Journal Of Clinical Nephrology
